---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-014833"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2025-03-26T23:59:59+00:00"
generated_at: "2026-05-24T04:55:45.161174+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Avalo Therapeutics appoints Michael Heffernan as Chairman, separating roles from CEO Garry Neil

## Summary
- Michael Heffernan appointed Chairman of the Board, effective March 25, 2025; succeeds Dr. Garry Neil who remains CEO and Board member.
- Heffernan brings experience building biopharma companies and executing exits; will guide pipeline including AVTX-009 in Phase 2 LOTUS trial for HS.
- Company states sufficient capital to achieve potentially transformative data readout from LOTUS trial next year.
- Board also approved Amended and Restated Non-Employee Director Compensation Plan to attract and retain qualified directors.

## SEC filing metadata
- accession: 0001628280-25-014833
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2025-03-26T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000162828025014833/0001628280-25-014833-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000162828025014833/avtx-20250325.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-014833
- JSON: https://secwatch.observer/filing/0001628280-25-014833.json
- Plain text: https://secwatch.observer/filing/0001628280-25-014833.txt

## Key facts
- Executive change
  Michael Heffernan was appointed as Chairman of the Board at Avalo Therapeutics, Inc..
  - Action: appointed
  - Role: Chairman of the Board
  source text: On March 25, 2025, the board of directors (the “ Board ”) of Avalo Therapeutics, Inc. (the “ Company ”) appointed Michael Heffernan to the Board, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534120/000162828025014833/0001628280-25-014833-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.